Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 372

1.

MMR vaccination and disease elimination: the Finnish experience.

Davidkin I, Kontio M, Paunio M, Peltola H.

Expert Rev Vaccines. 2010 Sep;9(9):1045-53. doi: 10.1586/erv.10.99. Review.

PMID:
20822347
[PubMed - indexed for MEDLINE]
2.

The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.

Peltola H, Heinonen OP, Valle M, Paunio M, Virtanen M, Karanko V, Cantell K.

N Engl J Med. 1994 Nov 24;331(21):1397-402.

PMID:
7969278
[PubMed - indexed for MEDLINE]
Free Article
3.

Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.

Bae GR, Choe YJ, Go UY, Kim YI, Lee JK.

Vaccine. 2013 May 31;31(24):2661-6. doi: 10.1016/j.vaccine.2013.04.014. Epub 2013 Apr 17.

PMID:
23602654
[PubMed - indexed for MEDLINE]
4.

An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States.

Zhou F, Reef S, Massoudi M, Papania MJ, Yusuf HR, Bardenheier B, Zimmerman L, McCauley MM.

J Infect Dis. 2004 May 1;189 Suppl 1:S131-45.

PMID:
15106102
[PubMed - indexed for MEDLINE]
Free Article
5.

Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up.

Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H.

J Infect Dis. 2008 Apr 1;197(7):950-6. doi: 10.1086/528993.

PMID:
18419470
[PubMed - indexed for MEDLINE]
Free Article
6.

Mumps and rubella eliminated from Finland.

Peltola H, Davidkin I, Paunio M, Valle M, Leinikki P, Heinonen OP.

JAMA. 2000 Nov 22-29;284(20):2643-7.

PMID:
11086376
[PubMed - indexed for MEDLINE]
7.

Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.

Nolan T, McIntyre P, Roberton D, Descamps D.

Vaccine. 2002 Dec 13;21(3-4):281-9.

PMID:
12450703
[PubMed - indexed for MEDLINE]
8.

Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP).

McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS; Centers for Disease Control and Prevention.

MMWR Recomm Rep. 2013 Jun 14;62(RR-04):1-34.

PMID:
23760231
[PubMed - indexed for MEDLINE]
Free Article
9.

Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Marin M, Broder KR, Temte JL, Snider DE, Seward JF; Centers for Disease Control and Prevention (CDC).

MMWR Recomm Rep. 2010 May 7;59(RR-3):1-12.

PMID:
20448530
[PubMed - indexed for MEDLINE]
Free Article
10.

Progress toward measles and rubella elimination in Egypt.

El Sayed N, Kandeel N, Barakat I, Moussa I, Alexander JP Jr, Naouri B, Reef SE.

J Infect Dis. 2011 Jul;204 Suppl 1:S318-24. doi: 10.1093/infdis/jir123.

PMID:
21666180
[PubMed - indexed for MEDLINE]
Free Article
11.

Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella.

Wellington K, Goa KL.

Drugs. 2003;63(19):2107-26. Review.

PMID:
12962524
[PubMed - indexed for MEDLINE]
12.

Rapid effect on endemic measles, mumps, and rubella of nationwide vaccination programme in Finland.

Peltola H, Karanko V, Kurki T, Hukkanen V, Virtanen M, Penttinen K, Nissinen M, Heinonen OP.

Lancet. 1986 Jan 18;1(8473):137-9.

PMID:
2867355
[PubMed - indexed for MEDLINE]
13.

Measles, mumps and rubella: control by vaccination.

van Druten JA, de Boo T, Plantinga AD.

Dev Biol Stand. 1986;65:53-63.

PMID:
3556777
[PubMed - indexed for MEDLINE]
14.

Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance.

Pebody RG, Gay NJ, Hesketh LM, Vyse A, Morgan-Capner P, Brown DW, Litton P, Miller E.

Vaccine. 2002 Jan 15;20(7-8):1134-40.

PMID:
11803074
[PubMed - indexed for MEDLINE]
15.

MMR vaccination, measles epidemiology and sero-surveillance in the Republic of Ireland.

Johnson H, Hillary IB, McQuoid G, Gilmer BA.

Vaccine. 1995 Apr;13(6):533-7.

PMID:
7483773
[PubMed - indexed for MEDLINE]
16.

Mumps incidence in Israel--impact of MMR vaccine.

Slater PE, Roitman M, Costin C.

Public Health Rev. 1990-1991;18(1):88-93.

PMID:
2132885
[PubMed - indexed for MEDLINE]
17.

Increased measles-mumps-rubella (MMR) vaccine uptake in the context of a targeted immunisation campaign during a measles outbreak in a vaccine-reluctant community in England.

Le Menach A, Boxall N, Amirthalingam G, Maddock L, Balasegaram S, Mindlin M.

Vaccine. 2014 Feb 26;32(10):1147-52. doi: 10.1016/j.vaccine.2014.01.002. Epub 2014 Jan 15.

PMID:
24440207
[PubMed - indexed for MEDLINE]
19.

Measles, mumps, and rubella: monitoring in Switzerland through a sentinel network, 1986-94. Sentinella Arbeitsgemeinschaft.

Matter HC, Cloetta J, Zimmermann H.

J Epidemiol Community Health. 1995 Aug;49 Suppl 1:4-8.

PMID:
7561669
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Increase of vaccination coverage by mass media and individual approach: intensified measles, mumps, and rubella prevention program in Finland.

Paunio M, Virtanen M, Peltola H, Cantell K, Paunio P, Valle M, Karanko V, Heinonen OP.

Am J Epidemiol. 1991 Jun 1;133(11):1152-60.

PMID:
2035518
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk